Proteomics International Managing Director Dr Richard Lipscombe said the research studied multiple proteins in the blood associated with early-stage oesophageal adenocarcinoma. “From these, we’ve been able to identify a select panel of biomarkers with the potential to be used as a diagnostic test. Importantly we have also completed validation of the panel using blood samples from more than 300 patients.”
